Guardant Health AMEA
Guardant Health Completes Purchase of Guardant Health AMEA Joint Venture
June 13, 2022 SINGAPORE– Guardant Health, Inc. (NASDAQ:GH), a leading precision oncology company, today announced it has purchased the remaining shares of
Guardant Health Receives Regulatory Approval for Guardant360® CDx in Japan
March 14, 2022 TOKYO, — The Ministry of Health, Labour and Welfare (MHLW) has granted regulatory approval of Guardant360® CDx, a liquid
Guardant Health AMEA Wins Frost & Sullivan’s Market Leadership Award for Liquid Biopsy in Precision Oncology in Asia, Middle East and Africa
December 15, 2020 MUMBAI, India — 15 December 2020 — Guardant Health Asia, Middle East and Africa (AMEA) has won Frost &
First liquid biopsy to receive FDA Approval for comprehensive tumor mutation profiling across all solid cancers, Guardant Health’s Guardant360® CDx, advancing precision oncology in Asia, Middle East and Africa
August 7, 2020 SINGAPORE — The U.S. Food and Drug Administration (FDA) has approved Guardant Health’s liquid biopsy, Guardant360 CDx, for tumor
Guardant360® test results may provide prognostic information beyond the detection of actionable biomarkers for ALK-rearranged NSCLC patients
May 30, 2020 SINGAPORE — According to the data presented at the American Society of Clinical Oncology (ASCO) Annual Meeting on 29 May 2020, researchers
Precision Oncology Company Guardant Health AMEA announces launch of its Asia, Middle East and Africa region headquarters in Singapore
November 23, 2018 SINGAPORE — Guardant Health AMEA today announces the launch of its Asia, Middle East and Africa headquarters in Singapore with the goal of addressing the unmet medical